Altered systemic bioavailability and organ distribution of azathioprine in methotrexate-induced intestinal mucositis in rats

被引:3
作者
Karbelkar, Sadaf A. [1 ]
Majumdar, Anuradha S. [1 ]
机构
[1] Bombay Coll Pharm, Dept Pharmacol, Bombay, Maharashtra, India
关键词
Azathioprine; bioavailability; intestinal mucositis; organ-distribution; pharmacokinetics; CITRULLINE; TOXICITY; INFLAMMATION; THERAPY; DISEASE; MARKER; ASSAY;
D O I
10.4103/0253-7613.182895
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Intestinal mucositis is a significant problem haunting clinicians for decades. One of the major reasons for its occurrence is high-dose chemotherapy. The study is aimed at investigating effect of intestinal mucositis on pharmacokinetics, organ distribution, and bioavailability of azathioprine (AZA) (6-mercaptopurine). Materials and Methods: Intestinal mucositis was induced with methotrexate (MTX) (2.5 mg/kg). The oral absorption of AZA and 6-mercaptopurine (metabolite) levels were determined in control and MTX-treated rats: ex vivo (noneverted sac technique) and in vivo (pharmacokinetics and organ-distribution) using high-performance liquid chromatography. Immunohistochemistry was conducted to evaluate peptide transporter expression on luminal membrane of small intestine. Results: Intestinal permeation of AZA into systemic circulation of rats was lower after MTX administration, widely found in intestinal segments of mucositis-induced rats leading to decline in systemic bioavailability of AZA. Immunohistochemistry findings indicated diminution of peptide transporter expression representing hampered absorption of drugs absorbed via this transporter. Conclusion: Study outcome has thrown light on altered fate of AZA when administered to individuals with mucositis which suggests modified drug therapy. These findings can further be investigated in different drug classes which might be administered concomitantly in mucositis and study outcome can be further confirmed in mucositis patients in clinical practice also.
引用
收藏
页码:241 / 247
页数:7
相关论文
共 25 条
  • [11] Contributions of mucosal immune cells to methotrexate-induced mucositis
    de Koning, Barbara A. E.
    van Dieren, Jolanda M.
    Lindenbergh-Kortleve, Dicky J.
    van der Sluis, Maria
    Matsumoto, Tetsuya
    Yamaguchi, Keizo
    Einerhand, Alexandra W.
    Samsom, Janneke N.
    Pieters, Rob
    Nieuwenhuis, Edward E. S.
    [J]. INTERNATIONAL IMMUNOLOGY, 2006, 18 (06) : 941 - 949
  • [12] Review article: oral and intestinal mucositis - causes and possible treatments
    Duncan, M
    Grant, G
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (09) : 853 - 874
  • [13] Development and validation of an HPLC method for the rapid and simultaneous determination of 6-mercaptopurine and four of its metabolites in plasma and red blood cells
    Hawwa, Ahmed F.
    Millership, Jeff S.
    Collier, Paul S.
    McElnay, James C.
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2009, 49 (02) : 401 - 409
  • [14] Jing S., 2010, THESIS
  • [15] Evaluation of Potential Gastrointestinal Biomarkers in a PAK4 Inhibitor-treated Preclinical Toxicity Model to Address Unmonitorable Gastrointestinal Toxicity
    John-Baptiste, Annette
    Huang, Wenhu
    Kindt, Erick
    Wu, Annette
    Vitsky, Allison
    Scott, Wes
    Gross, Cindy
    Yang, Amy H.
    Schaiff, W. Timothy
    Ramaiah, Shashi K.
    [J]. TOXICOLOGIC PATHOLOGY, 2012, 40 (03) : 482 - 490
  • [16] KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344
  • [17] PLASMA-CONCENTRATIONS AND ORGAN DISTRIBUTION OF THIOPURINES AFTER ORAL APPLICATION OF AZATHIOPRINE IN MICE
    KUROWSKI, V
    IVEN, H
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (01) : 7 - 14
  • [18] Impact of drug transporter studies on drug discovery and development
    Mizuno, N
    Niwa, T
    Yotsumoto, Y
    Sugiyama, Y
    [J]. PHARMACOLOGICAL REVIEWS, 2003, 55 (03) : 425 - 461
  • [19] Changes in absorptive function of rat intestine injured by methotrexate
    Naruhashi, K
    Nadai, M
    Nakao, M
    Suzuki, N
    Nabeshima, T
    Hasegawa, T
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2000, 27 (12) : 980 - 986
  • [20] Sedlak J., 2003, ANAL BIOCHEM, V95, P351